← Back to Search

Tyrosine Kinase Inhibitor

Jaktinib for Myelofibrosis

Phase 1
Research Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up at least 24 weeks, up to approximately 1 year
Awards & highlights


This trial is testing whether Jaktinib can shrink the size of the spleen and improve symptoms in people with myelofibrosis.

Who is the study for?
This trial is for adults over 18 with myelofibrosis who haven't responded well to standard treatments. They should be relatively stable (ECOG PS 0, 1, or 2) and expected to live more than 24 weeks. Pregnant or breastfeeding women can't join, nor those planning pregnancy without effective contraception.Check my eligibility
What is being tested?
The study is testing Jaktinib Hydrochloride Tablets as a new treatment option for Myelofibrosis. It's aimed at patients who have not had success with existing FDA-approved JAK inhibitors.See study design
What are the potential side effects?
While the specific side effects of Jaktinib are not listed here, similar drugs often cause issues like dizziness, headaches, nausea, low blood counts leading to increased infection risk or bleeding problems.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at least 24 weeks, up to approximately 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and at least 24 weeks, up to approximately 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose-limiting toxicities (DLTs) of jaktinib hydrochloride tablets
Safety of jaktinib hydrochloride tablets
Secondary outcome measures
Efficacy of jaktinib hydrochloride tablets
Tablet Dosage Form

Trial Design

1Treatment groups
Experimental Treatment
Group I: JaktinibExperimental Treatment1 Intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Janus kinase (JAK) inhibitors, such as ruxolitinib and the investigational drug Jaktinib, work by blocking the JAK-STAT signaling pathway, which is often overactive in Myelofibrosis. This pathway is crucial for the regulation of blood cell production and immune function. By inhibiting this pathway, JAK inhibitors can reduce the abnormal proliferation of blood cells and alleviate symptoms such as splenomegaly (enlarged spleen) and constitutional symptoms (e.g., fatigue, night sweats). This is particularly important for Myelofibrosis patients as it helps manage disease symptoms, improve quality of life, and potentially slow disease progression.

Find a Location

Who is running the clinical trial?

Suzhou Zelgen Biopharmaceuticals Co.,LtdLead Sponsor
66 Previous Clinical Trials
8,252 Total Patients Enrolled

Media Library

Jaktinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05279001 — Phase 1
Myelofibrosis Research Study Groups: Jaktinib
Myelofibrosis Clinical Trial 2023: Jaktinib Highlights & Side Effects. Trial Name: NCT05279001 — Phase 1
Jaktinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05279001 — Phase 1
~17 spots leftby May 2025